Trending News

Trump Administration Issues AI Action Plan and AI Executive Orders

Winning the Race: America’s AI Action Plan

Innovation Over Regulation – Trump Unveils America’s AI Action Plan

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
Posted On Wednesday, July 30, 2025
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
Posted On Wednesday, July 30, 2025
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Posted On Wednesday, July 30, 2025
Rakovina Therapeutics Announces Stock Option Grants
Posted On Tuesday, July 29, 2025
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
Posted On Tuesday, July 29, 2025
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
Posted On Tuesday, July 29, 2025
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
Posted On Tuesday, July 29, 2025
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
Posted On Tuesday, July 29, 2025
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
Posted On Tuesday, July 29, 2025
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
Posted On Tuesday, July 29, 2025
Altanine Names Charles J. Andres, Ph.D., J.D., as CEO to Lead Clinical and Strategic Expansion
Posted On Tuesday, July 29, 2025
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
Posted On Tuesday, July 29, 2025
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Posted On Tuesday, July 29, 2025
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
Posted On Tuesday, July 29, 2025
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
Posted On Tuesday, July 29, 2025
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference
Posted On Tuesday, July 29, 2025
Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery
Posted On Tuesday, July 29, 2025
Quoin Pharmaceuticals Provides Product Portfolio Update
Posted On Tuesday, July 29, 2025
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
Posted On Tuesday, July 29, 2025
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
Posted On Tuesday, July 29, 2025
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
Posted On Tuesday, July 29, 2025
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
Posted On Tuesday, July 29, 2025
RMS Announces 25% Wisconsin Tax Credit for Investing in Prospective Cure for Diabetes
Posted On Tuesday, July 29, 2025
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
Posted On Tuesday, July 29, 2025
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
Posted On Tuesday, July 29, 2025

First page
Previous page
…
7
8
9
10
11
12
13
14
15
…
Next page
Last page

Print